down arrow

Harpoon Therapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Biotechnology
  • ISIN: US41358P2056
USD
23.01
0.00 (0.00%)

Mar 12

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

0.000.00

52 Week

3.2123.21
Valuation
Technical
Day's Volume

CASH

0

Shareholding (Dec 2023)

FII

9.16%

Held by 28 FIIs

DII

63.77%

Held by 9 DIIs

Promoter

19.50%

How big is Harpoon Therapeutics, Inc.?

22-Jun-2025

As of Mar 12, Harpoon Therapeutics, Inc. has a market capitalization of 492.35 million and reported net sales of 37.34 million with a net profit of -30.50 million over the latest four quarters. As of Dec 22, shareholder's funds were 5.40 million and total assets were 73.73 million.

As of Mar 12, Harpoon Therapeutics, Inc. has a market capitalization of 492.35 million, categorizing it as a Micro Cap company.<BR><BR>As of Mar 12, the sum of net sales for the latest four quarters is 37.34 million, while the sum of net profit for the same period is -30.50 million.<BR><BR>As of Dec 22, the reporting period shows shareholder's funds of 5.40 million and total assets of 73.73 million.

Read More

What does Harpoon Therapeutics, Inc. do?

22-Jun-2025

Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company focused on T cell engagers for cancer treatment. As of September 2023, it reported net sales of $4 million and a net loss of $2 million, with a market cap of $492.35 million.

Overview: <BR>Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company in the biotechnology industry, focusing on T cell engagers to treat cancer and other diseases.<BR><BR>Financial Snapshot: <BR>Net Sales: 4 Million (Quarterly Results - Sep 2023) <BR>Net Profit: -2 Million (Quarterly Results - Sep 2023) <BR>Market cap: USD 492.35 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 181.12% <BR>Debt Equity: -6.31 <BR>Return on Equity: -380.31% <BR>Price to Book: 108.42<BR><BR>Contact Details: <BR>Address: 131 Oyster Point Blvd Ste 300, SOUTH SAN FRANCISCO CA 94080-1910 <BR>Tel: 1 650 4437400 <BR>Website: https://www.harpoontx.com/

Read More

Who are in the management team of Harpoon Therapeutics, Inc.?

22-Jun-2025

As of March 2022, the management team of Harpoon Therapeutics, Inc. includes Mr. Ronald Hunt as Chairman and Dr. Gerald McMahon as President and CEO, along with independent directors Mr. Joseph Bailes, Mr. Mark Chin, Dr. Jonathan Drachman, Ms. Julia Eastland, and Mr. Scott Myers.

As of March 2022, the management team of Harpoon Therapeutics, Inc. includes the following individuals:<BR><BR>- Mr. Ronald Hunt, Chairman of the Board<BR>- Dr. Gerald McMahon, President, Chief Executive Officer, and Director<BR><BR>Additionally, the Board of Directors comprises several independent directors: Mr. Joseph Bailes, Mr. Mark Chin, Dr. Jonathan Drachman, Ms. Julia Eastland, and Mr. Scott Myers.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
Icon
Unrated Stock - No Analysis Available
stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Biotechnology

stock-summary
Market cap

USD 492 Million (Micro Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

181.12%

stock-summary
Debt Equity

-6.31

stock-summary
Return on Equity

-380.31%

stock-summary
Price to Book

108.42

Revenue and Profits:
Net Sales:
4 Million
(Quarterly Results - Sep 2023)
Net Profit:
-2 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
162.97%
0%
162.97%
6 Months
237.89%
0%
237.89%
1 Year
248.64%
0%
248.64%
2 Years
-41.45%
0%
-41.45%
3 Years
-88.21%
0%
-88.21%
4 Years
-79.62%
0%
-79.62%
5 Years
-80.43%
0%
-80.43%

Harpoon Therapeutics, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News
Icon
No Recent News for the Company
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
68.70%
EBIT Growth (5y)
6.74%
EBIT to Interest (avg)
-49.16
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-6.31
Sales to Capital Employed (avg)
3.09
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
98.96%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
108.42
EV to EBIT
-12.40
EV to EBITDA
-13.41
EV to Capital Employed
-19.25
EV to Sales
12.42
PEG Ratio
NA
Dividend Yield
181.12%
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
-380.31%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
Bearish
No Signal
Bollinger Bands
Mildly Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Bearish
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2023stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 22 Schemes (7.57%)

Foreign Institutions

Held by 28 Foreign Institutions (9.16%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is -78.22% vs 134.88% in Jun 2023",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2023 is -263.64% vs 109.73% in Jun 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Sep'23",
        "Jun'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4.40",
          "val2": "20.20",
          "chgp": "-78.22%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-11.90",
          "val2": "4.80",
          "chgp": "-347.92%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "2.00",
          "val2": "1.60",
          "chgp": "25.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-11.20",
          "val2": "-2.00",
          "chgp": "-460.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-1.80",
          "val2": "1.10",
          "chgp": "-263.64%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,729.10%",
          "val2": "208.80%",
          "chgp": "-293.79%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'22",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2022 is 34.60% vs 36.21% in Dec 2021",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2022 is 41.99% vs -133.87% in Dec 2021",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'22",
        "Dec'21",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "31.90",
          "val2": "23.70",
          "chgp": "34.60%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-65.20",
          "val2": "-64.20",
          "chgp": "-1.56%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "-50.00",
          "chgp": "100.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-67.70",
          "val2": "-116.70",
          "chgp": "41.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-2,140.80%",
          "val2": "-2,823.90%",
          "chgp": "68.31%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Sep'23 - QoQstock-summary
Sep'23
Jun'23
Change(%)
Net Sales
4.40
20.20
-78.22%
Operating Profit (PBDIT) excl Other Income
-11.90
4.80
-347.92%
Interest
2.00
1.60
25.00%
Exceptional Items
-11.20
-2.00
-460.00%
Consolidate Net Profit
-1.80
1.10
-263.64%
Operating Profit Margin (Excl OI)
-2,729.10%
208.80%
-293.79%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2023 is -78.22% vs 134.88% in Jun 2023

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2023 is -263.64% vs 109.73% in Jun 2023

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'22stock-summary
Dec'22
Dec'21
Change(%)
Net Sales
31.90
23.70
34.60%
Operating Profit (PBDIT) excl Other Income
-65.20
-64.20
-1.56%
Interest
0.00
0.00
Exceptional Items
0.00
-50.00
100.00%
Consolidate Net Profit
-67.70
-116.70
41.99%
Operating Profit Margin (Excl OI)
-2,140.80%
-2,823.90%
68.31%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2022 is 34.60% vs 36.21% in Dec 2021

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2022 is 41.99% vs -133.87% in Dec 2021

All Annual Resultsstock-summary
stock-summaryCompany CV
About Harpoon Therapeutics, Inc. stock-summary
stock-summary
Harpoon Therapeutics, Inc.
Biotechnology
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company. The Company is engaged in a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases. T cell engagers are engineered proteins that direct a patient’s own T cells to kill target cells that express specific proteins, or antigens, carried by the target cells. Using its proprietary Tri-specific T cell Activating Construct, or TriTAC, platform, the Company is developing a pipeline of T cell engagers, or TriTACs, initially focused on the treatment of solid tumors and hematologic malignancies. Its TriTAC product candidate, HPN424, is focused on the treatment of metastatic castration-resistant prostate cancer, or mCRPC.
Company Coordinates stock-summary
Company Details
131 Oyster Point Blvd Ste 300 , SOUTH SAN FRANCISCO CA : 94080-1910
stock-summary
Tel: 1 650 4437400
stock-summary
https://www.harpoontx.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."